周五，AgomAb Therapeutics(AGMB.US)登陆美股市场，开盘跌超13%，IPO价格为16美元。AgomAb Therapeutics是一家临床阶段生物制药公司，致力于开发针对免疫与炎症疾病的创新疾病修正疗法。公 司初期战略聚焦于存在高度未满足医疗需求的慢性纤维化适应症，通过抑制纤维化关键信号通路——转 化生长因子-β(TGFβ)通路发挥作用。其核心候选药物ontunisertib(AGMB-129)是一种选择性、强效的口 服胃肠道限制性ALK5(即TGFβR1)小分子抑制剂，主要针对纤维狭窄型克罗恩病(FSCD)。 ...

智通财经APP获悉，周五，AgomAb Therapeutics(AGMB.US)登陆美股市场，开盘跌超13%，IPO价格为 16美元。AgomAb Therapeutics是一家临床阶段生物制药公司，致力于开发针对免疫与炎症疾病的创新 疾病修正疗法。公司初期战略聚焦于存在高度未满足医疗需求的慢性纤维化适应症，通过抑制纤维化关 键信号通路——转化生长因子-β(TGFβ)通路发挥作用。其核心候选药物ontunisertib(AGMB-129)是一种 选择性、强效的口服胃肠道限制性ALK5(即TGFβR1)小分子抑制剂，主要针对纤维狭窄型克罗恩病 (FSCD)。 ...

Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million. ...

ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the pricing of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a public offering price o ...

回顾：上周15只新股上市，含1家"直接上市"公司，如下： Public Policy Holding(PPHC)以每股12.25美元，发行了415万股，募集了5084万美元。 York Space System(YSS)以每股34美元，发行了1850万股，募集资金6.29亿美元。 Picpay(PICS)以每股19美元，发行了2286万股，募集资金4.34亿美元。 Ethos Technologies(LIFE)以每股19美元，发行了1053万股，募集资金2亿美元。 SPAC GigCapital9(GIXXU)、 Mountain Lake Acquisition II(MLAAU)、KRAKacquisition(KRAQU) 和 Space Asset Acquisition(SAAQU)、United Acquisition I(UACU)、Xsolla SPAC 1(XSLLU)、K2 Capital Acquisition(KTWOU)、M Evo Global Acquisition II(MEVOU)、Muzero Acquisition(MUZEU)、Newbridge Acquisitio ...

Group 1 - Four IPOs and ten SPACs were priced this week, indicating a robust activity in the capital markets [2] - York Space Systems (YSS), a satellite manufacturer, priced its upsized IPO at the top of the range, successfully raising $629 million [2] - Additionally, three IPOs and five SPACs submitted filings, suggesting a continued interest in public offerings [2]

智通财经APP获悉，比利时二期生物科技公司AgomAb Therapeutics(AGMB.US)于美东时间周四公布了 其美股IPO条款。该公司专注于开发针对克罗恩病及其他纤维化疾病的TGFβ抑制剂。公司计划以每股 15至17美元的价格发行1250万股，募集2亿美元资金。按拟议发行价区间中值计算，AgomAb Therapeutics的完全稀释后市值将达到8.75亿美元。 AgomAb Therapeutics是一家临床阶段生物制药公司，致力于开发针对免疫与炎症疾病的创新疾病修正 疗法。公司初期战略聚焦于存在高度未满足医疗需求的慢性纤维化适应症，通过抑制纤维化关键信号通 路——转化生长因子-β(TGFβ)通路发挥作用。 其核心候选药物ontunisertib(AGMB-129)是一种选择性、强效的口服胃肠道限制性ALK5(即TGFβR1)小 分子抑制剂，主要针对纤维狭窄型克罗恩病(FSCD)。 另一款临床阶段候选药物AGMB-447为吸入式ALK5小分子抑制剂，用于治疗特发性肺纤维化(IPF)。此 外，公司还拥有一款临床前阶段候选药物——一种靶向肝硬化的HGF模拟单克隆抗体;该公司已完成新 药临床试验申请所需 ...

Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources [1] Group 1 - IPO Edge offers first-look IPO filings, previews on upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a guide to IPO investing [1] - The guide walks investors through the entire IPO lifecycle, including filing, listing, quiet period, and lockup expiration dates [1]

TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on January 29, 2026. Registration Statement No. 333-292790 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AgomAb Therapeutics NV (Exact name of registrant as specified in its charter) 2836 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identification Number) (State or Other Jurisdiction ...

TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on January 16, 2026. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AgomAb Therapeutics NV (Exact name of registrant as specified in its charter) 2836 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identification Number) Posthoflei 1/6 2600 Antwerpen, Belgium Tel: +32 3 318 ...